Glenmark Life Sciences IPO is Coming soon

The Glenmark Life sciences  started in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It also deals in Contract Development and manufacturing operations (CDMO) to offer services to speciality Pharmaceutical companies.

Glenmark life sciences is selling their products in India as well as in multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing plants at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.

Competitive Advantage

Leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management.
Export products in Europe, Latin America, North America, Japan, and the rest of the world.
 • Best relationship with leading global generic pharma companies.
 • Well known track record of good financial performance.
 • High-quality product manufacturers with having their own R&D infrastructure.

Company Promoters:

Glenmark Pharmaceuticals Limited is the promoter of the company.

Objective of the IPO:

 • To make payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company.
 • To finance capital expenditure requirements.
 • To meet general corporate purposes.

Glenmark Life Sciences IPO Details

Issue Type - Book Built Issue IPO
Face Value - ₹2 per equity share
Listing At - BSE, NSE
Issue Size
Fresh Issue [.] Eq Shares of ₹2
(aggregating up to ₹1,160.00 Cr)
Offer for Sale 7,305,245 Eq Shares of ₹2
(aggregating up to ₹[.] Cr)

Comments

Popular posts from this blog

Macd Indicator for beginners